Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$201.3 million for Q3 2025.

• On a quarterly basis, Cash from Investing Activities rose 22.4% year-over-year to -$201.3 million in Q3 2025; TTM through Sep 2025 was -$183.1 million, a 32.65% increase from a year earlier, with the FY2024 full-year figure at -$286.8 million, down 1516.15% from the prior year.
• Cash from Investing Activities eased to -$201.3 million in Q3 2025 per DNTH's latest filing, from $26.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $29.9 million in Q2 2021 and bottomed at -$259.4 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is -$5.5 million (2024), against an average of -$23.3 million.
• Across the five-year window, Cash from Investing Activities surged 17048.84% in 2023 and tumbled 2154.36% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$10.3 million in 2021, then slipped by 22.69% to -$12.7 million in 2022, then soared by 34.96% to -$8.2 million in 2023, then tumbled by 180.56% to -$23.1 million in 2024, then slumped by 770.94% to -$201.3 million in 2025.
• Per Business Quant, the three latest DNTH Cash from Investing Activities figures stand at -$201.3 million (Q3 2025), $26.4 million (Q2 2025), and $14.8 million (Q1 2025).